Deal covers monoclonal and polyclonal antibodies that bind biomarkers including those for cancer.
Rockland Immunochemicals inked a licensing venture with LIMR Development (LDI), the business development subsidiary of the Lankenau Institute for Medical Research (LIMR). Rockland Immunochemicals will market LDI’s entire portfolio of LIMR monoclonal and polyclonal antibodies.
LDI’s antibodies bind biomarkers crucial for cell signaling, immune system regulation, inflammatory responses, cellular metabolism, and cancer progression. “LIMR’s work in cancer and inflammation is an elegant fit with Rockland’s antibody portfolio and technology platform,” remarks James Fendrick, president and CEO of Rockland Immunochemicals.
“We partner with leading institutions to bring to researchers the reagents vital to the advance of their key research,” Fendrick adds. Rockland Immunochemicals focuses on antibodies and antibody-based tools for basic research, diagnostic assay development, and preclinical studies. It develops new technologies for the production of antibodies for western blotting, immunohistochemistry, immunofluorescence microscopy, ELISA, and flow cytometry.